Former Bristol Exec Albright Named CSO of Editas
Cambridge, MA-based gene editing company Editas Medicine (NASDAQ: EDIT) has named Charles Albright its chief scientific officer. Albright was most recently the VP of genetically defined diseases and genomics at Bristol-Myers Squibb, and held positions at Incyte and DuPont Pharmaceuticals before that.
Underwriters and Partners
Xpertise: Watch + Learn
Xconomy Insight · Special Report
Starting a Biotech Company: What Every Entrepreneur Needs to Know
Get advice from the experts to help your biotech startup succeed
From Our Editors · Special Report
2019 Biopharma Outlook – Facing an Uncertain Future
Facing an Uncertain Future
Xconomy
Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX
From Our Advertisers
Wisconsin helps biotech company raise $20 million
See how TAI Diagnostics achieved accelerated growth
Wisconsin Economic Development Corporation